1.57

10.80% -0.19

Pre-market: 1.64 0.07 +4.46%

Aptevo Therapeutics Inc (APVO)

Overview News Price History Financials Discussions Forecast Stock Split

Aptevo Therapeutics Inc stock is traded at $1.57, with a volume of 2.71M. It is down -10.80% in the last 24 hours and up +4.67% over the past month. Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Previous Close:

$1.76

Open:

$1.69

24h Volume:

2.71M

Relative Volume:

0.55

Market Cap:

$5.16M

Revenue:

$12.99M

Net Income/Loss:

$-23.72M

P/E Ratio:

-0.0161

EPS:

-97.2514

Net Cash Flow:

$-23.28M

1W Performance:

+9.79%

1M Performance:

+4.67%

6M Performance:

-92.00%

1Y Performance:

-98.58%

1-Day Range:

$1.56

$1.7299

1-Week Range:

$1.41

$1.98

52-Week Range:

$1.32

$381.10

Aptevo Therapeutics Inc Stock (APVO) Company Profile

Name

Aptevo Therapeutics Inc

Sector

Healthcare (1140)

Industry

Biotechnology (637)

Phone

206-838-0500

Address

2401 4TH AVE., SEATTLE, WA

Employee

Twitter

@aptevo

Next Earnings Date

2024-11-12

Latest SEC Filings

APVO's Discussions on Twitter

Compare APVO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APVO Aptevo Therapeutics Inc	1.57	24.30M	12.99M	-23.72M	-23.28M	-97.25
VRTX Vertex Pharmaceuticals Inc	407.79	106.37B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	460.46	59.90B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	564.63	60.40B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	796.92	49.56B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.10	36.88B	4.56B	-176.77M	225.30M	-1.7177

Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-05-18	Initiated	Ladenburg Thalmann	Buy
Oct-05-17	Resumed	Piper Jaffray	Overweight

Aptevo Therapeutics Inc Stock (APVO) Latest News

01:44 AM

Top chart patterns to watch in Aptevo Therapeutics Inc.2025 EndofYear Setup & Growth Focused Stock Pick Reports - newser.com

01:44 AM

Oct 12, 2025

Tools to assess Aptevo Therapeutics Inc.’s risk profileDividend Hike & AI Enhanced Trade Execution Alerts - newser.com

Oct 12, 2025

How sustainable is Aptevo Therapeutics Inc. stock dividend payoutJuly 2025 Volume & Free Community Supported Trade Ideas - newser.com

Oct 12, 2025

How to forecast Aptevo Therapeutics Inc. trends using time seriesJuly 2025 Analyst Calls & Community Trade Idea Sharing Platform - newser.com

Oct 12, 2025

Does Aptevo Therapeutics Inc. show high probability of reboundWeekly Market Report & Low Volatility Stock Recommendations - newser.com

Oct 12, 2025

Oct 10, 2025

Is Aptevo Therapeutics Inc. (AP81) stock inflation resilientWeekly Investment Report & Low Drawdown Momentum Ideas - newser.com

Oct 10, 2025

Relative strength of Aptevo Therapeutics Inc. in sector analysisChart Signals & Stock Timing and Entry Methods - newser.com

Oct 10, 2025

What’s the recovery path for long term holders of Aptevo Therapeutics Inc.July 2025 Update & Consistent Return Strategy Ideas - newser.com

Oct 10, 2025

Will Aptevo Therapeutics Inc. stock outperform international peers2025 Top Gainers & High Win Rate Trade Tips - newser.com

Oct 10, 2025

Why analysts raise outlook for Aptevo Therapeutics Inc. (AP81) stockJuly 2025 WrapUp & Weekly Setup with ROI Potential - newser.com

Oct 10, 2025